Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Abbott Laboratories (Pakistan) 9-Day RSI Related Terms
KAR:ABOT vs ZTS, UTHR, VTRS: 9-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Abbott Laboratories (Pakistan)'s 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbott Laboratories (Pakistan) 9-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Abbott Laboratories (Pakistan)'s 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Abbott Laboratories (Pakistan)'s 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbott Laboratories (Pakistan) (KAR:ABOT) has a 9-Day RSI of 54.30 as of Jul. 17, 2026. According to the industry distribution chart, Abbott Laboratories (Pakistan) ranks #556 out of 1049 companies in the Drug Manufacturers industry, placing it in the top 53%.
Is Abbott Laboratories (Pakistan)'s 9-Day RSI too high?
Abbott Laboratories (Pakistan)'s current 9-Day RSI is 54.30. The Drug Manufacturers industry median 9-Day RSI is 53.26. Abbott Laboratories (Pakistan)'s value of 54.30 is 2% above this industry median. Based on the distribution chart, Abbott Laboratories (Pakistan) ranks #556 out of 1049 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Abbott Laboratories (Pakistan) has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Abbott Laboratories (Pakistan)'s 9-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Abbott Laboratories (Pakistan) ranks #556 out of 1049 companies for 9-Day RSI. This places Abbott Laboratories (Pakistan) in the lower half of its industry. The industry median 9-Day RSI is 53.26. Abbott Laboratories (Pakistan)'s value of 54.30 is 2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Drug Manufacturers company?
The median 9-Day RSI among Drug Manufacturers companies is 53.26, based on 1,049 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Abbott Laboratories (Pakistan)'s current 9-Day RSI of 54.30 is 2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median 9-Day RSI is 53.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbott Laboratories (Pakistan)'s current 9-Day RSI is 54.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbott Laboratories (Pakistan) stock overvalued right now?
Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) (KAR:ABOT) is currently considered Fairly Valued. The stock's GF Value™ is ₨1,009.68, compared to a current price of ₨970.80 — trading 3.9% below its estimated fair value. The current 9-Day RSI is 54.30 and 2% above the Drug Manufacturers industry median of 53.26. Abbott Laboratories (Pakistan)'s overall GF Score™ is 76/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Abbott Laboratories (Pakistan) (KAR:ABOT), the current 9-Day RSI is 54.30 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbott Laboratories (Pakistan) (KAR:ABOT) Overvalued in 2026?
Based on GuruFocus' analysis, Abbott Laboratories (Pakistan) stock appears to be undervalued.
The current stock price of ₨970.80 is trading 3.9% below its estimated GF Value™ of ₨1,009.68.
GuruFocus considers Abbott Laboratories (Pakistan) to be Fairly Valued.
Key valuation signals for KAR:ABOT:
9-Day RSI: 54.30
GF Value™: ₨1,009.68 vs. price of ₨970.80 (3.9% below fair value)
Industry Position: 2% above the Drug Manufacturers median (#556 of 1049)
No single metric tells the full story. See the KAR:ABOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbott Laboratories (Pakistan) Business Description
Abbott Laboratories (Pakistan) Ltd manufactures, imports, and markets research-based pharmaceutical, nutritional, diagnostic, diabetes care, molecular devices, hospital, and consumer products. Its operating segments are Pharmaceutical, Nutritional, Diagnostics, and Others. It generates maximum revenue from the Pharmaceutical segment. Geographically, it derives the majority of its revenue from Pakistan and has a presence in Afghanistan, Sri Lanka, Bangladesh, and Switzerland. The company's Brands include Duphaston, Brufen, Surbex Z, Arinac, Glucerna, Pediasure, and Ensure.
76GF Score
Get the complete analysis for KAR:ABOT
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KAR:ABOT has been successfully added to your 
